Connect with us

Hi, what are you looking for?


The Week Ahead in Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts in Focus in Final Week of Year

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.

The week’s news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. Pfizer, Inc. (NYSE: PFE) received authorization for its oral drug Paxlovid on Wednesday, followed by Merck & Co., Inc.’s (NYSE: MRK) molnupiravir.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.

Allakos Inc. (NASDAQ: ALLK) was among the worst performers of the week after the company’s investigational compound flunked late-stage studies in inflammation of the digestive tract.

Here are the key biopharma …

Full story available on


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to...


The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu Arjun’s Pushpa Is Out… The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu...


Kyle Rittenhouse testifies about Gaige Grosskreutz holding a gun toward him during his trial at the Kenosha County Courthouse on November 10, 2021 in...


PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the “Company”)), a biotechnology company with operations in China and the...